Lawyer Claims Merck Canceled Vioxx Study After FDA Decision

Merck was planning a study on the cardiac risks of Vioxx but scrapped the project in March of 2002 soon after the FDA decided to tone down its warning about heart risks. The FDA and Merck agreed that a notice should be added in the precautions section of the drug's label rather than a more conspicuous warning section. Merck's former head of marketing claims the decision on the study and the labeling were merely coincidence. Linda A. Johnson, Houston Chronicle 06/16/2006 Read Article: Houston Chronicle